Horizon Pharma PLC  

(Public, NASDAQ:HZNP)   Watch this stock  
Find more results for HZNP
-0.14 (-1.18%)
After Hours: 11.73 0.00 (0.00%)
Jun 23, 4:17PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 11.49 - 11.93
52 week 9.45 - 23.44
Open 11.87
Vol / Avg. 4.85M/4.97M
Mkt cap 1.91B
P/E     -
Div/yield     -
EPS -1.31
Shares 162.71M
Beta 1.86
Inst. own 89%

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin -41.01% -17.00%
Operating margin -47.96% -15.00%
EBITD margin - 14.34%
Return on average assets -8.38% -4.54%
Return on average equity -29.42% -12.95%
Employees 1,030 -
CDP Score - -


Dublin 4 1st Fl 1 Burlington Road, Connaught House
+353-1-7722100 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units. The Company's marketed medicines are ACTIMMUNE (interferon gamma-1b), BUPHENYL (sodium phenylbutyrate) Tablets and Powder, DUEXIS (ibuprofen/famotidine), KRYSTEXXA (pegloticase), MIGERGOT (ergotamine tartrate & caffeine suppositories), PENNSAID (diclofenac sodium topical solution) 2% weight per weight (w/w), or PENNSAID 2%, PROCYSBI (cysteamine bitartrate) delayed-release capsules, QUINSAIR (aerosolized form of levofloxacin), RAVICTI (glycerol phenylbutyrate) Oral Liquid, RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium).

Officers and directors

Timothy P. Walbert Chairman of the Board, President, Chief Executive Officer
Age: 48
Bio & Compensation  - Reuters
Paul W. Hoelscher Chief Financial Officer, Executive Vice President
Age: 51
Bio & Compensation  - Reuters
Brian K. Beeler Executive Vice President, General Counsel
Age: 43
Bio & Compensation  - Reuters
David G. Kelly Executive Vice President, Company Secretary and Managing Director, Ireland
Age: 55
Bio & Compensation  - Reuters
John B. Thomas Executive Vice President, Strategy and Investor Relations
Age: 52
Bio & Compensation  - Reuters
Robert F. Carey Executive Vice President, Chief Business Officer
Age: 57
Bio & Compensation  - Reuters
George P. Hampton Executive Vice President - Orphan and Primary Care Business Units and International Operations
Age: 46
Bio & Compensation  - Reuters
Jeffrey W. Sherman M.D. Executive Vice President - Research and Development and Chief Medical Officer
Age: 61
Bio & Compensation  - Reuters
Timothy J. Ackerman Senior Vice President - Commercial Operations
Age: 49
Bio & Compensation  - Reuters
Geoffrey M. Curtis Senior Vice President - Corporate Communications
Age: 41
Bio & Compensation  - Reuters